HHS backs down in le­gal fight over drug dis­count pro­gram with As­traZeneca, Eli Lil­ly, No­vo and Sanofi

HHS’ Of­fice of the Gen­er­al Coun­sel late Fri­day with­drew an ad­vi­so­ry opin­ion from De­cem­ber “in light of on­go­ing con­fu­sion” about its scope and im­pact, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER